Long-term and sequential treatment for osteoporosis
- PMID: 37464088
- DOI: 10.1038/s41574-023-00866-9
Long-term and sequential treatment for osteoporosis
Abstract
Osteoporosis is a skeletal disorder that causes impairment of bone structure and strength, leading to a progressively increased risk of fragility fractures. The global prevalence of osteoporosis is increasing in the ageing population. Owing to the chronic character of osteoporosis, years or even decades of preventive measures or therapy are required. The long-term use of bone-specific pharmacological treatment options, including antiresorptive and/or osteoanabolic approaches, has raised concerns around adverse effects or potential rebound phenomena after treatment discontinuation. Imaging options, risk scores and the assessment of bone turnover during initiation and monitoring of such therapies could help to inform individualized treatment strategies. Combination therapies are currently used less often than 'sequential' treatments. However, all patients with osteoporosis, including those with secondary and rare causes of osteoporosis, as well as specific patient populations (for example, young adults, men and pregnant women) require new approaches for long-term therapy and disease monitoring. New pathophysiological aspects of bone metabolism might therefore help to inform and revolutionize the diagnosis and treatment of osteoporosis.
© 2023. Springer Nature Limited.
Similar articles
-
Sequential therapy in the treatment of osteoporosis.Curr Med Res Opin. 2011 Jun;27(6):1149-55. doi: 10.1185/03007995.2011.573545. Epub 2011 Apr 5. Curr Med Res Opin. 2011. PMID: 21466276 Review.
-
Combination antiresorptive and osteoanabolic therapy for osteoporosis: we are not there yet.Curr Med Res Opin. 2011 Sep;27(9):1705-7. doi: 10.1185/03007995.2011.599837. Epub 2011 Jul 11. Curr Med Res Opin. 2011. PMID: 21740288
-
Osteoporosis in premenopausal women.Curr Opin Rheumatol. 2017 Jul;29(4):410-415. doi: 10.1097/BOR.0000000000000400. Curr Opin Rheumatol. 2017. PMID: 28394826 Review.
-
Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.J Manag Care Pharm. 2012 May;18(4 Suppl B):S1-15; discussion S13. doi: 10.18553/jmcp.2012.18.s4-b.1. J Manag Care Pharm. 2012. PMID: 22716221 Free PMC article.
-
Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis.J Clin Endocrinol Metab. 2024 Jan 18;109(2):303-311. doi: 10.1210/clinem/dgad496. J Clin Endocrinol Metab. 2024. PMID: 37610985 Review.
Cited by
-
Neoandrographolide inhibits mature osteoclast differentiation to alleviate bone loss and treat osteoporosis.Front Pharmacol. 2025 Feb 11;16:1466057. doi: 10.3389/fphar.2025.1466057. eCollection 2025. Front Pharmacol. 2025. PMID: 40008134 Free PMC article.
-
Bioenergetic programs of cancellous and cortical bone are distinct and differ with age and mechanical loading.Sci Rep. 2025 May 31;15(1):19134. doi: 10.1038/s41598-025-02141-5. Sci Rep. 2025. PMID: 40450018 Free PMC article.
-
Advances in Functionalized Nanoparticles for Osteoporosis Treatment.Int J Nanomedicine. 2025 Jun 20;20:7869-7891. doi: 10.2147/IJN.S519945. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40557247 Free PMC article. Review.
-
Identification of mitophagy-related biomarkers in human osteoporosis based on a machine learning model.Front Physiol. 2024 Jan 8;14:1289976. doi: 10.3389/fphys.2023.1289976. eCollection 2023. Front Physiol. 2024. PMID: 38260098 Free PMC article.
-
Sildenafil promotes osteogenic differentiation of human mesenchymal stem cells and inhibits bone loss by affecting the TGF-β signaling pathway.Stem Cell Res Ther. 2025 Apr 23;16(1):201. doi: 10.1186/s13287-025-04320-7. Stem Cell Res Ther. 2025. PMID: 40264229 Free PMC article.
References
-
- Zengin, A., Prentice, A. & Ward, K. A. Ethnic differences in bone health. Front. Endocrinol. 6, 24 (2015).
-
- Trajanoska, K. et al. Assessment of the genetic and clinical determinants of fracture risk: genome wide association and Mendelian randomisation study. Br. Med. J. 362, k3225 (2018).
-
- Schweighofer, N. et al. DXA-derived indices in the characterisation of sarcopenia. Nutrients 14, 186 (2022).
-
- Collins, M. T. et al. Skeletal and extraskeletal disorders of biomineralization. Nat. Rev. Endocrinol. 18, 473–489 (2022). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical